{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T13:07:59Z","timestamp":1792069679940,"version":"4.4.0"},"reference-count":39,"publisher":"American Society of Hematology","issue":"24","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2021,6,17]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Richter syndrome (RS) represents the transformation of chronic lymphocytic leukemia (CLL), typically to an aggressive lymphoma. Treatment options for RS are limited and the disease is often fatal. Receptor tyrosine kinase\u2013like orphan receptor 1 (ROR1) is expressed on CLL cells and other cancers but not on healthy adult tissues, making it an attractive, tumor-specific therapeutic target. VLS-101 is being developed as an antibody-drug conjugate (ADC) for therapy of ROR1-expressing (ROR1+) cancers. VLS-101 comprises UC-961 (a humanized immunoglobulin G1 monoclonal antibody that binds an extracellular epitope of human ROR1), a maleimidocaproyl-valine-citrulline-para-aminobenzoate linker, and the antimicrotubule cytotoxin monomethyl auristatin E (MMAE). VLS-101 binding to ROR1 results in rapid cellular internalization and delivery of MMAE to induce tumor cell death. We studied 4 RS patient-derived xenografts (RS-PDXs) with varying levels of ROR1 expression (11%, 32%, 85%, and 99% of cells). VLS-101 showed no efficacy in the lowest-expressing RS-PDX but induced complete remissions in those with higher levels of ROR1 expression. Responses were maintained during the posttherapy period, particularly after higher VLS-101 doses. In systemic ROR1+ RS-PDXs, VLS-101 dramatically decreased tumor burden in all RS-colonized tissues and significantly prolonged survival. Animals showed no adverse effects or weight loss. Our results confirm ROR1 as a target in RS and demonstrate the therapeutic potential of using an ADC directed toward ROR1 for the treatment of hematological cancers. A phase 1 clinical trial of VLS-101 (NCT03833180) is ongoing in patients with RS and other hematological malignancies.<\/jats:p>","DOI":"10.1182\/blood.2020008404","type":"journal-article","created":{"date-parts":[[2021,1,14]],"date-time":"2021-01-14T22:01:39Z","timestamp":1610661699000},"page":"3365-3377","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":94,"title":["ROR1 targeting with the antibody-drug conjugate VLS-101 is effective in Richter syndrome patient\u2013derived xenograft mouse models"],"prefix":"10.1182","volume":"137","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3375-6985","authenticated-orcid":false,"given":"Tiziana","family":"Vaisitti","sequence":"first","affiliation":[{"name":"Department of Medical Sciences, University of Torino, Turin, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5298-9314","authenticated-orcid":false,"given":"Francesca","family":"Arruga","sequence":"additional","affiliation":[{"name":"Department of Medical Sciences, University of Torino, Turin, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicoletta","family":"Vitale","sequence":"additional","affiliation":[{"name":"Department of Medical Sciences, University of Torino, Turin, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8679-5243","authenticated-orcid":false,"given":"Thanh-Trang","family":"Lee","sequence":"additional","affiliation":[{"name":"VelosBio, Inc, San Diego, CA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mira","family":"Ko","sequence":"additional","affiliation":[{"name":"VelosBio, Inc, San Diego, CA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy","family":"Chadburn","sequence":"additional","affiliation":[{"name":"NewYork-Presbyterian Hospital, Weill Cornell Medicine, New York, NY;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esteban","family":"Braggio","sequence":"additional","affiliation":[{"name":"Department of Hematology and Oncology, Mayo Clinic in Arizona, Scottsdale, AZ; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3159-5380","authenticated-orcid":false,"given":"Arianna","family":"Di Napoli","sequence":"additional","affiliation":[{"name":"Pathology Unit, Department of Clinical and Molecular Medicine, Sant\u2019Andrea Hospital, Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8940-1406","authenticated-orcid":false,"given":"Andrea","family":"Iannello","sequence":"additional","affiliation":[{"name":"Department of Medical Sciences, University of Torino, Turin, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2088-0899","authenticated-orcid":false,"given":"John N.","family":"Allan","sequence":"additional","affiliation":[{"name":"NewYork-Presbyterian Hospital, Weill Cornell Medicine, New York, NY;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Langdon L.","family":"Miller","sequence":"additional","affiliation":[{"name":"VelosBio, Inc, San Diego, CA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian J.","family":"Lannutti","sequence":"additional","affiliation":[{"name":"VelosBio, Inc, San Diego, CA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard R.","family":"Furman","sequence":"additional","affiliation":[{"name":"NewYork-Presbyterian Hospital, Weill Cornell Medicine, New York, NY;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katti A.","family":"Jessen","sequence":"additional","affiliation":[{"name":"VelosBio, Inc, San Diego, CA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0632-5036","authenticated-orcid":false,"given":"Silvia","family":"Deaglio","sequence":"additional","affiliation":[{"name":"Department of Medical Sciences, University of Torino, Turin, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"7","key":"2021061715214148500_B1","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1007\/s13238-014-0059-7","article-title":"ROR1, an embryonic protein with an emerging role in cancer biology","volume":"5","author":"Borcherding","year":"2014","journal-title":"Protein Cell"},{"issue":"1","key":"2021061715214148500_B2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/dvdy.21991","article-title":"Ror-family receptor tyrosine kinases in noncanonical Wnt signaling: their implications in developmental morphogenesis and human diseases","volume":"239","author":"Minami","year":"2010","journal-title":"Dev Dyn"},{"issue":"4","key":"2021061715214148500_B3","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1007\/s004270100140","article-title":"Expression of the Ror1 and Ror2 receptor tyrosine kinase genes during mouse development","volume":"211","author":"Al-Shawi","year":"2001","journal-title":"Dev Genes Evol"},{"issue":"12","key":"2021061715214148500_B4","doi-asserted-by":"crossref","first-page":"e52655","DOI":"10.1371\/journal.pone.0052655","article-title":"Restricted cell surface expression of receptor tyrosine kinase ROR1 in pediatric B-lineage acute lymphoblastic leukemia suggests targetability with therapeutic monoclonal antibodies","volume":"7","author":"Dave","year":"2012","journal-title":"PLoS One"},{"issue":"8","key":"2021061715214148500_B5","doi-asserted-by":"crossref","first-page":"3047","DOI":"10.1073\/pnas.0712148105","article-title":"Antisera induced by infusions of autologous Ad-CD154-leukemia B cells identify ROR1 as an oncofetal antigen and receptor for Wnt5a","volume":"105","author":"Fukuda","year":"2008","journal-title":"Proc Natl Acad Sci USA"},{"issue":"5","key":"2021061715214148500_B6","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1016\/j.ccr.2012.08.027","article-title":"Crosstalk between ROR1 and the Pre-B cell receptor promotes survival of t(1;19) acute lymphoblastic leukemia","volume":"22","author":"Bicocca","year":"2012","journal-title":"Cancer Cell"},{"issue":"6","key":"2021061715214148500_B7","doi-asserted-by":"crossref","first-page":"1903","DOI":"10.1016\/j.ajpath.2012.08.024","article-title":"The onco-embryonic antigen ROR1 is expressed by a variety of human cancers","volume":"181","author":"Zhang","year":"2012","journal-title":"Am J Pathol"},{"issue":"3","key":"2021061715214148500_B8","doi-asserted-by":"crossref","first-page":"e31127","DOI":"10.1371\/journal.pone.0031127","article-title":"ROR1 is expressed in human breast cancer and associated with enhanced tumor-cell growth","volume":"7","author":"Zhang","year":"2012","journal-title":"PLoS One"},{"issue":"4","key":"2021061715214148500_B9","doi-asserted-by":"crossref","first-page":"843","DOI":"10.3109\/10428194.2012.731599","article-title":"Orphan receptor tyrosine kinases ROR1 and ROR2 in hematological malignancies","volume":"54","author":"Daneshmanesh","year":"2013","journal-title":"Leuk Lymphoma"},{"issue":"3","key":"2021061715214148500_B10","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1016\/j.ccr.2012.02.008","article-title":"NKX2-1\/TITF1\/TTF-1-Induced ROR1 is required to sustain EGFR survival signaling in lung adenocarcinoma","volume":"21","author":"Yamaguchi","year":"2012","journal-title":"Cancer Cell"},{"issue":"2","key":"2021061715214148500_B11","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1172\/JCI83535","article-title":"Wnt5a induces ROR1\/ROR2 heterooligomerization to enhance leukemia chemotaxis and proliferation","volume":"126","author":"Yu","year":"2016","journal-title":"J Clin Invest"},{"issue":"6","key":"2021061715214148500_B12","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1038\/leu.2016.368","article-title":"Cirmtuzumab inhibits Wnt5a-induced Rac1 activation in chronic lymphocytic leukemia treated with ibrutinib","volume":"31","author":"Yu","year":"2017","journal-title":"Leukemia"},{"issue":"2","key":"2021061715214148500_B13","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1038\/ncb3464","article-title":"A ROR1-HER3-lncRNA signalling axis modulates the Hippo-YAP pathway to regulate bone metastasis","volume":"19","author":"Li","year":"2017","journal-title":"Nat Cell Biol"},{"issue":"2","key":"2021061715214148500_B14","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1158\/1078-0432.CCR-07-1823","article-title":"Unique cell surface expression of receptor tyrosine kinase ROR1 in human B-cell chronic lymphocytic leukemia","volume":"14","author":"Baskar","year":"2008","journal-title":"Clin Cancer Res"},{"issue":"1","key":"2021061715214148500_B15","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1002\/hon.948","article-title":"ROR1 expression is not a unique marker of CLL","volume":"29","author":"Barna","year":"2011","journal-title":"Hematol Oncol"},{"issue":"25","key":"2021061715214148500_B16","doi-asserted-by":"crossref","first-page":"2931","DOI":"10.1182\/blood-2016-04-712562","article-title":"High-level ROR1 associates with accelerated disease progression in chronic lymphocytic leukemia","volume":"128","author":"Cui","year":"2016","journal-title":"Blood"},{"issue":"2","key":"2021061715214148500_B17","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1073\/pnas.1308374111","article-title":"ROR1 can interact with TCL1 and enhance leukemogenesis in E\u03bc-TCL1 transgenic mice","volume":"111","author":"Widhopf","year":"2014","journal-title":"Proc Natl Acad Sci USA"},{"issue":"12","key":"2021061715214148500_B18","doi-asserted-by":"crossref","first-page":"3391","DOI":"10.1182\/blood-2010-09-302174","article-title":"The genetics of Richter syndrome reveals disease heterogeneity and predicts survival after transformation","volume":"117","author":"Rossi","year":"2011","journal-title":"Blood"},{"issue":"15","key":"2021061715214148500_B19","doi-asserted-by":"crossref","first-page":"2673","DOI":"10.1182\/blood-2013-03-489518","article-title":"Two main genetic pathways lead to the transformation of chronic lymphocytic leukemia to Richter syndrome","volume":"122","author":"Chigrinova","year":"2013","journal-title":"Blood"},{"issue":"2","key":"2021061715214148500_B20","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1053\/j.seminoncol.2016.02.012","article-title":"Richter syndrome: pathogenesis and management","volume":"43","author":"Rossi","year":"2016","journal-title":"Semin Oncol"},{"key":"2021061715214148500_B21","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1182\/asheducation-2018.1.1","article-title":"On the architecture of translational research designed to control chronic lymphocytic leukemia","volume":"2018","author":"Hallek","year":"2018","journal-title":"Hematology Am Soc Hematol Educ Program"},{"issue":"4","key":"2021061715214148500_B22","doi-asserted-by":"crossref","first-page":"IJH09","DOI":"10.2217\/ijh-2018-0010","article-title":"Current trends in the management of Richter\u2019s syndrome","volume":"7","author":"Allan","year":"2019","journal-title":"Int J Hematol Oncol"},{"issue":"17","key":"2021061715214148500_B23","doi-asserted-by":"crossref","first-page":"2965","DOI":"10.1182\/blood-2013-06-506741","article-title":"Infusion of donor-derived CD19-redirected virus-specific T cells for B-cell malignancies relapsed after allogeneic stem cell transplant: a phase 1 study [published correction appears in Blood. 2014;123(21):3364]","volume":"122","author":"Cruz","year":"2013","journal-title":"Blood"},{"issue":"6","key":"2021061715214148500_B24","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1200\/JCO.2014.56.2025","article-title":"Chemotherapy-refractory diffuse large B-cell lymphoma and indolent B-cell malignancies can be effectively treated with autologous T cells expressing an anti-CD19 chimeric antigen receptor","volume":"33","author":"Kochenderfer","year":"2015","journal-title":"J Clin Oncol"},{"issue":"6","key":"2021061715214148500_B25","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1056\/NEJMoa1910607","article-title":"Use of CAR-transduced natural killer cells in CD19-positive lymphoid tumors","volume":"382","author":"Liu","year":"2020","journal-title":"N Engl J Med"},{"issue":"26","key":"2021061715214148500_B26","doi-asserted-by":"crossref","first-page":"3419","DOI":"10.1182\/blood-2017-02-765685","article-title":"Pembrolizumab in patients with CLL and Richter transformation or with relapsed CLL","volume":"129","author":"Ding","year":"2017","journal-title":"Blood"},{"issue":"2","key":"2021061715214148500_B27","doi-asserted-by":"crossref","first-page":"e67","DOI":"10.1016\/S2352-3026(18)30217-5","article-title":"Safety and activity of ibrutinib in combination with nivolumab in patients with relapsed non-Hodgkin lymphoma or chronic lymphocytic leukaemia: a phase 1\/2a study","volume":"6","author":"Younes","year":"2019","journal-title":"Lancet Haematol"},{"issue":"26","key":"2021061715214148500_B28","doi-asserted-by":"crossref","first-page":"3010","DOI":"10.1200\/JCO.2017.72.8519","article-title":"Durable molecular remissions in chronic lymphocytic leukemia treated with CD19-specific chimeric antigen receptor-modified T cells after failure of ibrutinib","volume":"35","author":"Turtle","year":"2017","journal-title":"J Clin Oncol"},{"issue":"1","key":"2021061715214148500_B29","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1002\/hon.2464","article-title":"Ibrutinib-induced rapid response in chemotherapy-refractory Richter\u2019s syndrome","volume":"36","author":"Fischer","year":"2018","journal-title":"Hematol Oncol"},{"issue":"suppl","key":"2021061715214148500_B30","doi-asserted-by":"crossref","first-page":"S167","DOI":"10.1016\/j.clml.2015.02.010","article-title":"Pre-clinical specificity and safety of UC-961, a first-in-class monoclonal antibody targeting ROR1","volume":"15","author":"Choi","year":"2015","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"6","key":"2021061715214148500_B31","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1016\/j.stem.2018.05.018","article-title":"Phase I trial: cirmtuzumab inhibits ROR1 signaling and stemness signatures in patients with chronic lymphocytic leukemia","volume":"22","author":"Choi","year":"2018","journal-title":"Cell Stem Cell"},{"issue":"suppl 1","key":"2021061715214148500_B32","article-title":"Development of cirmtuzumab antibody-drug conjugates (ADCs) targeting receptor tyrosine kinase-like orphan receptor 1 (ROR1) [abstract]","volume":"132","author":"Mian","year":"2018","journal-title":"Blood"},{"issue":"13","key":"2021061715214148500_B33","doi-asserted-by":"crossref","first-page":"3413","DOI":"10.1158\/0008-5472.CAN-17-4004","article-title":"Novel Richter syndrome xenograft models to study genetic architecture, biology, and therapy responses","volume":"78","author":"Vaisitti","year":"2018","journal-title":"Cancer Res"},{"issue":"5","key":"2021061715214148500_B34","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1158\/2159-8290.CD-12-0095","article-title":"The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data","volume":"2","author":"Cerami","year":"2012","journal-title":"Cancer Discov"},{"issue":"269","key":"2021061715214148500_B35","doi-asserted-by":"crossref","first-page":"pl1","DOI":"10.1126\/scisignal.2004088","article-title":"Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal","volume":"6","author":"Gao","year":"2013","journal-title":"Sci Signal"},{"key":"2021061715214148500_B36","volume-title":"WHO Classification of Tumors of Haematopoietic and Lymphoid Tissues.","author":"Swerdlow","year":"2017","edition":"4th ed"},{"issue":"4","key":"2021061715214148500_B37","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1056\/NEJMoa1509981","article-title":"Acalabrutinib (ACP-196) in relapsed chronic lymphocytic leukemia","volume":"374","author":"Byrd","year":"2016","journal-title":"N Engl J Med"},{"issue":"9","key":"2021061715214148500_B38","doi-asserted-by":"crossref","first-page":"2710","DOI":"10.1158\/0008-5472.CAN-15-1795","article-title":"Intracellular released payload influences potency and bystander-killing effects of antibody-drug conjugates in preclinical models","volume":"76","author":"Li","year":"2016","journal-title":"Cancer Res"},{"issue":"12","key":"2021061715214148500_B39","doi-asserted-by":"crossref","first-page":"1736","DOI":"10.1038\/bjc.2017.367","article-title":"Antibody drug conjugates and bystander killing: is antigen-dependent internalisation required?","volume":"117","author":"Staudacher","year":"2017","journal-title":"Br J Cancer"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/137\/24\/3365\/1809291\/bloodbld2020008404.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/137\/24\/3365\/1809291\/bloodbld2020008404.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,17]],"date-time":"2023-10-17T18:22:11Z","timestamp":1697566931000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/137\/24\/3365\/474956\/ROR1-targeting-with-the-antibody-drug-conjugate"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6,17]]},"references-count":39,"journal-issue":{"issue":"24","published-print":{"date-parts":[[2021,6,17]]}},"URL":"https:\/\/doi.org\/10.1182\/blood.2020008404","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,6,17]]}}}